Sanofi SA

SAN

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    82,878

Stocks News & Analysis

retirement

The top shares of Australia’s best performing super funds

And our equity analysts’ outlook for the stocks.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,841.908.300.09%
CAC 407,696.2758.28-0.75%
DAX 4023,787.45146.68-0.61%
Dow JONES (US)44,828.53344.110.77%
FTSE 1008,822.910.29-0.00%
HKSE23,916.06153.88-0.64%
NASDAQ20,601.10207.971.02%
Nikkei 22539,810.8824.980.06%
NZX 50 Index12,766.6062.120.49%
S&P 5006,279.3551.930.83%
S&P/ASX 2008,603.007.200.08%
SSE Composite Index3,472.3211.170.32%

Market Movers